Table 4.
Previously reported VEGF concentration (pg/mL) in aqueous humor of eyes with age-related macular degeneration.
| Area | Subtype | N | Mean | SD | SEM | 95%PI | Median | IQR | Measurement Method | |
|---|---|---|---|---|---|---|---|---|---|---|
| Hu et al. [154] | China | Refractory PCV * | 41 | 55 | 27 | - | - | 52 | - | Immunoassay using multi-analyte biochip array (RANDOX laboratories) |
| Stable PCV * | 39 | 43 | 23 | - | - | 33 | - | |||
| Sasaki et al. [155] | Japan | PCV | 62 | 55 | - | 5 | - | 59 | 23-84 | ELISA using Q-Plex kit (Quansys Biosciences) |
| Nomura et al. [156] | Japan | tnAMD/PCV with PVD | 13 | 58 | - | - | 25-137 | - | - | ELISA using Quantikine Kit (R&D Systems) |
| tnAMD/PCV without PVD | 20 | 91 | - | - | 31-267 | - | - | |||
| Lee MY et al. [157] | Korea | PCV | 21 | 62 | - | 37 | - | - | - | Multiplex bead immunoassay using LINCOplex kit (LINCO Research) |
| Kim JH et al. [158] | Korea | nAMD | 30 | 63 | 32 | - | - | - | - | ELISA using human VEGF immunoassay (Thermo Fischer Scientific) |
| Agawa T et al. [159] | Japan | tnAMD/PCV | 37 | 67 | 43 | - | - | - | - | Flow cytometry using Cytometric Bead Array (PharMingen) |
| Roh MI et al. [160] | Korea | Naïve nAMD | 5 | 67 | 35 | - | - | - | - | Multiplex biochip immunoassay using Cytokine Array (RANDOX laboratories) |
| Recurrent nAMD | 14 | 56 | 63 | - | - | - | - | |||
| Roh MI et al. [161] | Korea | nAMD | 10 | 68 | 32 | - | - | - | - | Immunoassay using multi-analyte biochip array (RANDOX laboratories) |
| Sakurada Y et al. [162] | Japan | PCV | 22 | 69 | 27 | - | - | - | - | ELISA using Q-Plex kit (Quansys Biosciences) |
| tnAMD | 18 | 71 | 16 | - | - | - | - | |||
| Wang X et al. [163] | Japan | tnAMD/PCV with monthly ranibizumab treatment | 9 | 95 | 32 | - | - | - | - | ELISA using Quantikine Kit (R&D Systems) |
| tnAMD/PCV with bimonthly ranibizumab treatment | 17 | 152 | 80 | - | - | - | - | |||
| Chan WM et al. [164] | Hong Kong | tnAMD | 34 | 103 | 91 | - | - | - | - | ELISA using ChemiKine kit (Chemicon International) |
| Cha DM et al. [165] | Korea | tnAMD | 20 | 122 | 63 | - | - | - | - | RayBio Biotin Label-Based Cytokine Antibody Array (RayBiotech) |
| Sato T et al. [166] | Japan | tnAMD/PCV | 21 | 228 | 176 | - | - | - | - | Multiplex bead immunoassay using Bio-Plex kit (Bio-rad) |
| Tong JP et al. [167] | Hong Kong | PCV | 11 | 403 | 230 | - | - | - | - | ELISA using ChemiKine kit (Chemicon International) |
| tnAMD | 12 | 669 | 340 | - | - | - | - |
SD, standard deviation; SEM, standard error of the mean; PI, prediction interval; IQR, interquartile range; PCV, polypoidal choroidal vasclopathy; tnAMD, typical neovascular age-related macular degeneration; nAMD, neovascular age-related macular degeneration; ELISA, enzyme-linked immunosorbent assay; PVD, posterior vitreous detachment. * Refractory PCV patients were defined as those showing signs of recurrence or persistence of the lesions at 12 months follow-up after the latest treatment/re-treatment with anti-VEGF monotherapy or combination of photodynamic therapy and anti VEGF treatment, while stable PCV patients were defined as those whose polyps completely regressed at 12 months follow-up.